DNA4Life's new report uses patients' DNA to avoid ADRs
"By securely and responsibly making access to personalized, quality data – and care – an affordable reality, DNA4Life has the potential to revolutionize drug therapy for the most common health conditions that are managed with medication," Richard Zimmer III, co-founder and CEO, DNA4Life, said. "Our differentiated and more comprehensive analysis will assist healthcare professionals in customizing a personalized treatment plan for their patients of all ages, ethnicities and genders – particularly those being treated for chronic conditions, like high cholesterol, depression, ADHD or pain."
Zimmer added that DNA4Life's analysis allows healthcare providers to more accurately prescribe, adjust and change a patient’s prescription(s), reducing trial-and-error, medication errors and treatment costs.
Until now, physicians have relied almost exclusively on the trial-and-error approach to finding the right medication or combination of medications to effectively manage and control health conditions, costing patients, on average, $1,000 per year.
Worse yet, trial-and-error can lead to medication errors and/or serious – or even fatal – adverse drug reactions (ADRs). According to the U.S. Food and Drug Administration, ADRs are the 4th leading cause of death in the United States today.